Afficher la notice abrégée

Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials

dc.rights.licenseopenen_US
dc.contributor.authorLEREBOURS, F.
dc.contributor.authorPULIDO, M.
dc.contributor.authorFOURME, E.
dc.contributor.authorDEBLED, M.
dc.contributor.authorBECETTE, V.
dc.contributor.authorBONNEFOI, H.
dc.contributor.authorRIVERA, S.
dc.contributor.authorMACGROGAN, G.
dc.contributor.authorMOURET-REYNIER, M. A.
dc.contributor.authorDE LARA, C. T.
dc.contributor.authorPIERGA, J. Y.
dc.contributor.authorBRETON-CALLU, C.
dc.contributor.authorVENAT-BOUVET, L.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMATHOULIN-PELISSIER, Simone
dc.contributor.authorDE LA MOTTE ROUGE, T.
dc.contributor.authorDALENC, F.
dc.contributor.authorSIGAL, B.
dc.contributor.authorBACHELOT, T.
dc.contributor.authorLEMONNIER, J.
dc.contributor.authorQUENEL-TUEUX, N.
dc.date.accessioned2021-02-02T15:53:20Z
dc.date.available2021-02-02T15:53:20Z
dc.date.issued2020
dc.identifier.issn1532-1827 (Electronic) 0007-0920 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26100
dc.description.abstractEnBackground Few data are available on survival and predictive factors in early breast cancer (BC) patients treated with neoadjuvant endocrine therapy (NET). Methods This is a pooled analysis of two multicentre, randomised non-comparative phase 2 clinical trials evaluating neoadjuvant anastrozole and fulvestrant efficacy for postmenopausal HR+/HER2- breast cancer patients: HORGEN (NCT00871858) and CARMINA02 (NCT00629616) studies. Results In total, 236 patients were included in CARMINA02 and HORGEN trials. Modified intention-to-treat analysis was available for 217 patients. Median follow-up was 65.2 months. Relapse-free survival (RFS) and overall survival (OS) at 5 years were 83.7% (95% CI: 77.9–88) and 92.7% (95% CI: 88.2–95.6), respectively, with no difference between treatment arms. On univariate analysis, tumour staging (T2 vs T3–4; p = 0.0001), Ki-67 at surgery (≤10% vs >10%; p = 0.0093), pathological tumour size (pT1–2 vs pT3–4; p = 0.0012) and node status (pN negative vs positive; p = 0.007), adjuvant chemotherapy (p = 0.0167) and PEPI score (PEPI group I + II vs III; p = 0.0004) were associated with RFS. No events were observed in patients with pathological response according to the Sataloff classification. Multivariate analysis showed that preoperative endocrine prognostic index (PEPI) group III was associated with significantly worse RFS (p = 0.0069, hazard ratio = 3.33 (95% CI: 1.39–7.98)). Conclusions Postmenopausal HR+/HER2- breast cancer patients receiving NET generally have a favourable outcome. The PEPI score identifies a subset of patients of poorer prognosis who are candidates for further additional treatment.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectEPICENE
dc.title.enPredictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
dc.title.alternativeBr J Canceren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1038/s41416-020-0733-xen_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
bordeaux.journalBritish Journal of Canceren_US
bordeaux.page759-765en_US
bordeaux.volume122en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamEPICENEen_US
bordeaux.teamEPICENE_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British%20Journal%20of%20Cancer&rft.date=2020&rft.volume=122&rft.issue=6&rft.spage=759-765&rft.epage=759-765&rft.eissn=1532-1827%20(Electronic)%200007-0920%20(Linking)&rft.issn=1532-1827%20(Electronic)%200007-0920%20(Linking)&rft.au=LEREBOURS,%20F.&PULIDO,%20M.&FOURME,%20E.&DEBLED,%20M.&BECETTE,%20V.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_BJC_2020_Lerebours.pdf
Taille:
629.5Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée